557 related articles for article (PubMed ID: 19710553)
1. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
Kyriakou A; Patsatsi A; Sotiriadis D
J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
[TBL] [Abstract][Full Text] [Related]
3. Off-label dermatologic uses of anti-TNF-a therapies.
Alexis AF; Strober BE
J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation].
Levy-Roy A; Porcher R; de Fonclare AL; Morel P; Dupuy A
Ann Dermatol Venereol; 2009 Apr; 136(4):315-22. PubMed ID: 19361697
[TBL] [Abstract][Full Text] [Related]
5. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
6. Biological agents in the treatment of psoriasis.
Tzu J; Krulig E; Cardenas V; Kerdel FA
G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
[TBL] [Abstract][Full Text] [Related]
7. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the tumor necrosis factor antagonists.
Bachmann F; Nast A; Sterry W; Philipp S
Semin Cutan Med Surg; 2010 Mar; 29(1):35-47. PubMed ID: 20430306
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
10. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
12. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.
Bansback N; Sizto S; Sun H; Feldman S; Willian MK; Anis A
Dermatology; 2009; 219(3):209-18. PubMed ID: 19657180
[TBL] [Abstract][Full Text] [Related]
13. Infliximab treatment in psoriatic arthritis: our experience.
Rioda WT; Adorni G
Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
[TBL] [Abstract][Full Text] [Related]
14. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
[TBL] [Abstract][Full Text] [Related]
15. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
16. [Anti-TNF alpha in the treatment of psoriatic arthritis].
Claudepierre P; Wendling D; Cohen JD
Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
[TBL] [Abstract][Full Text] [Related]
17. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
[TBL] [Abstract][Full Text] [Related]
18. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
Van L; Modi SV; Yang DJ; Hsu S
Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
[No Abstract] [Full Text] [Related]
19. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
[TBL] [Abstract][Full Text] [Related]
20. Newer treatment options for patients with moderate-to-severe psoriatic disease.
Roebuck HL
Nurse Pract; 2006 Aug; 31(8):5-6,11. PubMed ID: 16966969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
